Trophos treats last patient in ALS Phase three drug trial
During the trial, Olesoxime is dosed at 330mg oral capsules once a day and riluzole is dosed in both arms at 50mg twice a day. In total, the
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.